NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72237-0102-07 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
00078-1098-30 | 00078-1098 | asciminib | SCEMBLIX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Oral | Oct 29, 2021 | In Use | |
72237-0102-06 | 72237-0102 | selinexor | XPOVIO | 40.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | May 19, 2021 | In Use | |
61748-0304-11 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
00469-0125-99 | 00469-0125 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 31, 2012 | In Use | |
52125-0515-01 | 52125-0515 | Methylprednisolone Sodium Succinate | Solu-Medrol | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intravenous | Feb 13, 2013 | Feb 13, 2014 | No Longer Used |
00555-0607-02 | 00555-0607 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Nov 30, 1995 | In Use | ||
61748-0304-01 | 61748-0304 | Isotretinoin | Myorisan | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | May 1, 2012 | In Use | |
42254-0160-01 | 42254-0160 | Aprepitant | Emend | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Mar 26, 2003 | In Use | |
76388-0880-25 | 76388-0880 | Thioguanine | Tabloid | 40.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Mar 12, 2013 | Mar 31, 2025 | No Longer Used |
55150-0262-03 | 55150-0262 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 40.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Dec 15, 2015 | In Use | |
70437-0240-26 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Jul 17, 2017 | In Use | |
00469-1725-56 | 00469-1725 | Enzalutamide | Xtandi | 40.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug 4, 2020 | In Use | |
50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
70710-1025-08 | 70710-1025 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
53808-0614-01 | 53808-0614 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Jul 1, 2009 | In Use | ||
54868-1629-01 | 54868-1629 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Jul 5, 2007 | In Use | ||
71335-2181-01 | 71335-2181 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Oct 25, 2022 | In Use | ||
00003-4040-60 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
70771-1560-04 | 70771-1560 | Isotretinoin | Isotretinoin | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 12, 2023 | In Use | |
10631-0118-31 | 10631-0118 | Isotretinoin | Absorica | 40.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jun 8, 2012 | In Use | |
63739-0165-10 | 63739-0165 | Megestrol Acetate | Megestrol Acetate | 40.0 mg/1 | Hormonal Therapy | Progestin Analog | Oral | Aug 8, 1988 | Jul 31, 2021 | No Longer Used | |
42388-0025-46 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 9, 2023 | In Use | |
13668-0591-81 | 13668-0591 | APREPITANT | APREPITANT | 40.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct 21, 2020 | In Use | |
00143-9136-01 | 00143-9136 | Mitomycin | Mitomycin | 40.0 mg/1 | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Oct 1, 2022 | In Use |
Found 11564 results — Export these results